1111 Discovery Novel Allosteric Fragment Inhibitors of HIV-1 Reverse Transcriptase for HIV Prevention A/Prof Gilda Tachedjian Retroviral Biology and Antivirals.

Slides:



Advertisements
Similar presentations
Analysis of High-Throughput Screening Data C371 Fall 2004.
Advertisements

DR. SHABANA ALI (Asso. Prof.) Kd- Dissociation constant.
Improving Gleevec: Insight from the Receptor Structure Gleevec cannot bind to the open (active) form of the Abl kinase - would collide with open conformation.
In silico small molecule discovery Sales Target gene Discover hit Hit to lead Optimise lead Clinical Target gene identified with a viable assay High throughput.
Chemical Biology 1 – Pharmacology Methods for studying protein function – Loss of Function 1. Gene knockouts 2. Conditional knockouts 3. RNAi.
Jürgen Sühnel Institute of Molecular Biotechnology, Jena Centre for Bioinformatics Jena / Germany Supplementary Material:
Lipinski’s rule of five
 Structure-based drug design:  The macromolecular target can be isolated and crystallized…then the structure will be determined using X-ray crystallography.
Establishing a Successful Virtual Screening Process Stephen Pickett Roche Discovery Welwyn.
Nucleotide Chemistry and Biochemistry at SLU Michael B. Doughty Associate Professor of Biochemistry Department of Chem & Phys Southeastern Louisiana University.
FBDD Advantages? Disadvantages? What is a fragment?
BACE-1 Inhibitors Alzheimer’s Disease Application of Fragment-Based NMR Screening, X-ray Crystallography, Structure-Based Design, and Focused Chemical.
Design of Small Molecule Drugs Targeted to RNA RNA Ontology Group May
What do all of these have in common?. Natural Products Drug Discovery Searching for Cures in the Plant Kingdom They all contain natural products…
Anti-HIV Drugs Cathy Molina November 11, Some HIV Facts HIV – the Human Immunodeficiency Virus is the retrovirus that causes AIDS HIV belongs to.
Structure-based Drug Design
Factors Influencing Enzyme Action
Antivirals for HIV Yasir Waheed, PhD. Some HIV Facts HIV – the Human Immunodeficiency Virus is the retrovirus that causes AIDS HIV belongs to the retrovirus.
Computational Techniques in Support of Drug Discovery October 2, 2002 Jeffrey Wolbach, Ph. D.
NUS CS5247 A dimensionality reduction approach to modeling protein flexibility By, By Miguel L. Teodoro, George N. Phillips J* and Lydia E. Kavraki Rice.
Rational Drug Design Soma Mandal, Mee'nal Moudgil, Sanat K. Mandal.
A genetic algorithm for structure based de-novo design Scott C.-H. Pegg, Jose J. Haresco & Irwin D. Kuntz February 21, 2006.
CS 790 – Bioinformatics Introduction and overview.
AIDS, Vienna 2010 MOAA01 Novel therapeutic strategies The LEDGINs: rational design of first in class LEDGF/p75-integrase inhibitors with potent antiviral.
Different methods for structure elucidation. Spectroscopy: Studying the properties of matter through its interaction with different frequency components.
DE NOVO DESIGN OF A THYMIDYLATE KINASE INHIBITOR.
Anti-HIV Drugs Melissa Morgan Medicinal Chemistry November 23, 2004.
Function first: a powerful approach to post-genomic drug discovery Stephen F. Betz, Susan M. Baxter and Jacquelyn S. Fetrow GeneFormatics Presented by.
1 © Patrick An Introduction to Medicinal Chemistry 3/e Chapter 9 DRUG DISCOVERY: FINDING A LEAD Part 4: (Lead compounds - Impact of the human genome project)
In silico discovery of inhibitors using structure-based approaches Jasmita Gill Structural and Computational Biology Group, ICGEB, New Delhi Nov 2005.
Ligand-based drug discovery No a priori knowledge of the receptor What information can we get from a few active compounds.
 Receptors are mostly membrane-bound proteins that selectively bind small molecules called ligands which results in physiological response.  They are.
Samudrala group - overall research areas CASP6 prediction for T Å C α RMSD for all 70 residues CASP6 prediction for T Å C α RMSD for all.
1 © Patrick An Introduction to Medicinal Chemistry 3/e Chapter 10 DRUG DESIGN: OPTIMIZING TARGET INTERACTIONS Part 2: Section 10.2.
Virtual Screening C371 Fall INTRODUCTION Virtual screening – Computational or in silico analog of biological screening –Score, rank, and/or filter.
Hierarchical Database Screenings for HIV-1 Reverse Transcriptase Using a Pharmacophore Model, Rigid Docking, Solvation Docking, and MM-PB/SA Junmei Wang,
Structure- based Structure-based computer-aided drug discovery (SB-CADD) approach: helps to design and evaluate the quality, in terms of affinity, of series.
Ensemble Approaches Yield New Scaffolds and New Binding Sites Heather A. Carlson Department of Medicinal Chemistry College of Pharmacy University of Michigan.
High-Throughput Screening Core Facility at CU-Boulder Wei Wang
Retrovirus HIV (humans) Animal viruses resulting in cancer / AIDS 15-39%
Elon Yariv Graduate student in Prof. Nir Ben-Tal’s lab Department of Biochemistry and Molecular Biology, Tel Aviv University.
Pharmaceutical Approaches to Antiviral Drug Discovery
Key topics about enzyme function:
Molecular Modeling in Drug Discovery: an Overview
TIDEA Target (and Lead) Independent Drug Enhancement Algorithm.
Kalyan Das CABM & Rutgers University, NJ, USA
Julia Salas CS379a Aim of the Study To determine distinguishing features of orally administered drugs –Physical and structural features probed.
1 © Patrick An Introduction to Medicinal Chemistry 3/e Chapter 9 DRUG DISCOVERY: FINDING A LEAD Part 1: Sections
Structure-based inhibitor design and validation: Application to Plasmodium falciparum glutathione S-transferase Marli Botha MSc. Bioinformatics.
Screening of allosteric inhibitors and inhibitors of protein-protein interactions Joel Eggert.
Structural Bioinformatics Elodie Laine Master BIM-BMC Semester 3, Genomics of Microorganisms, UMR 7238, CNRS-UPMC e-documents:
Lipinski’s rule of five
Effect of inhibitor binding on the 1H-15N HSQC spectra of RGS4.
Can Drug Discovery Research be Done At An Undergraduate Institution?
Application of High-Throughput Methodology to Human Drug Targets
Drug/Target Validation
Nuclear magnetic resonance NMR spectroscopy is a key analytical technique for structure elucidation of a wide range of materials from small molecules to.
Factors Influencing Enzyme Action – V2
DATA MINING FOR SMALL MOLECULE ALLOSTERIC INHIBITORS
An Introduction to Medicinal Chemistry 3/e
Ligand-Based Structural Hypotheses for Virtual Screening
HIV Integrase Therapeutics
Bradley Croy Doak, Bjӧrn Over, Fabrizio Giordanetto, Jan Kihlberg 
Branko Stefanovic Biomedical Sciences
Fragment to lead (to drug) optimization
Volume 16, Issue 10, Pages (October 2009)
Cheminformatics Basics
ORGANIC PHARMACEUTICAL CHEMISTRY IV
Patrick: An Introduction to Medicinal Chemistry 6e
Presentation transcript:

1111 Discovery Novel Allosteric Fragment Inhibitors of HIV-1 Reverse Transcriptase for HIV Prevention A/Prof Gilda Tachedjian Retroviral Biology and Antivirals Laboratory Centre for Biomedical Research Burnet Institute

2222 Discover Novel Allosteric Inhibitors of HIV-1 RT Polymerase active site NNRTI binding pocket RNase H active site HIV RT inhibitors approved or being developed for oral and topical PrEP same drug classes used for therapy Potential for drug resistance in the context of PrEP use in a real life setting 13 RT inhibitors used in the clinic they only belong to two classes: NRTIs and NNRTIs Conformational flexibility of RT – function Additional druggable allosteric sites in RT

3333 “Fragments” are chemicals MW < 250 Da More efficient at probing the chemical space – sample greater chemical diversity by screening a smaller library Bind with weak affinity Strategically elaborated into larger high affinity inhibitors Validated approach – US FDA approved drug Vemurafinib Fragment Based Drug Discovery (FBDD)

4444 Three Novel Fragments Inhibit NNRTI Resistant HIV-1 RT Inhibition of HIV-1 RT DDDP 4A2 inhibits RNase H IC µM Screen 13% 1.1%

5555 V89 and 4A2 Competes with Template/Primer and Cell culture data 4A2 inhibits HIV-1 EC ± 4 µM 4A2 Competes with T/P IC ± 1 µM V89 Competes with dNTP Ki 220 ± 74 µM

6666 Identified fragments with novel scaffolds and modes of action compared to HIV RT inhibitors used clinically Structure activity relationship (SAR) and X-ray crystallography studies are in progress to: - identify optimised fragments (more potent than original hits) - identify binding sites on HIV-1 RT - elaborate fragments into potent inhibitors by structure-based drug design Summary

7777 Tachedjian Lab Univ of Pittsburgh Nicolas Sluis-Cremer Acknowledgments Rutgers University Eddy Arnold Joe Bauman Monash Institute of Pharmaceutical Sciences (MIPS) David Chalmers Martin Scanlon Steve Headey Jennifer La Cath Latham David Tyssen Adam Johnson

8888 Detects weak binders Can screen mixtures of compounds (x 5) Pulse saturates entire protein (receptor) with magnetization transferring to protein bound ligand Once ligand dissociates, saturated ligands can be detected Resonances of small fragments not directly affected by pulse Magnetic Field RT fragment Dissociate Magnetisation transfer to fragment Detect bound fragments Saturation Transfer Difference Nuclear Magnetic Resonance (STD NMR)

9999 Library of 630 fragments (ave MW 208) - Astex “Rule of Three” to make sure fragment like i.e. mass≤300 Da, ≤3 H-bond acceptors, ≤3H-bond donors, a clogP of ≤3, rotatable bonds ≤3 and a polar surface <60A 2 Maybridge Ro3 library Fragment Library

10 Fragments are generally less potent against MoMLV and do not inhibit Klenow DNA pol